Hello Slushers :)
Slush China 2020
'Reboot the Future' online pitching
Session 4 - Health Tech is Coming!
Pitch Date & Time
2020.5.22
15:00 - 17:00 (UTC+8)
On 22nd May, Slush China will hold the Health Tech International Online Pitching and invite investors, corporates, startups, incubators, media(up to 300 attendees) to join us. After pitching, we will hold an Online Panel, focusing on the integration of innovative technology and the health sector, international cooperation in Health Tech, not only providing a match-making platform for attendees but also giving them industry and customer insights. In addition, as the sponsor, AWS Activate Program will provide all the participating startups AWS Promotional Credits to help them grow better.
5月22日，Slush中国'重启未来' 线上路演系列活动第4季 -“健康科技”主题线上路演将邀请投资人，大企业，初创企业、孵化器及媒体代表等（300名参会者）参与。路演后，我们也将组织国际投资人与医疗专家组成圆桌，重点讨论创新技术与医疗行业的融合，国际医疗技术合作等前沿话题，希望不仅为参会者提供匹配对接平台，也能为大家提供一些行业干货。此外，AWS云将作为活动赞助商，为初创企业提供云服务抵扣券，助力他们的成长。
In the past few months, during the recession, the sectors of medical equipment, healthcare services, digital health, and other related fields have grown against the fall. In the first quarter in 2020, the global Health Tech field raised 25.956 billion US dollars, a growth of 42.46% comparing to the last year. COVID-19 has greatly impacted people's living and working style, posed great challenges to the national healthcare systems, and the global economy, it also created opportunities for startups in the health tech sector to go forward.
在资本寒冬下，医疗设备，医疗服务，数字医疗和其他医疗领域逆势增长。仅2020年第一季度，全球医疗领域融资就达到259.56亿美元，比去年同期增长42.46％。新型冠状病毒疫情极大地改变了人们的生活，给国家医疗保健系统和全球经济带来了巨大挑战，同时也为健康科技领域的初创企业提供了发展的机会。
What Will You Get ?
1. Matchmaking chance with top investors, corporates, leading-edge startups and other leaders in the health tech industry, including Zhenfund, MicroPort, GTJA Investment Group, Linear Capital, Hillhouse, ShuLan health,etc.
2. Free AWS credit - As a sponsor for Slush China online pitching series, AWS Activate Program will provide all the participating startups 5k USD (or 30k RMB) AWS Promotional Credits.
3. Opportunity to present on the pitching stage of Slush Shanghai on Oct. 15&16th, a 15k-people top annual global tech&startup event.
你将获得什么？
1. 和顶级投资人、医疗集团、初创企业进行匹配对接的机会，包括真格基金、微创医疗、高特佳医疗投资集团、高瓴资本、树兰医疗、阿斯利康等。
2. 免费AWS云额度- AWS云创计划为报名路演的初创公司提供3万元人民币或者5,000美金的AWS云服务抵扣券。
3. 在10月15和16日Slush上海万人大会现场路演舞台上获得对媒体、投资人、潜在大企业合作伙伴的曝光。
How to Join the Pitch
Scan the QR Code in the poster or click here to sign up before 1 pm, May 15th (UTC+8).
Search [Hello_Slushers] and add on WeChat. You’ll be invited into our WeChat group for this online pitching for more information, interaction, and communication with other participants.
如何报名参与本次路演？
[扫描]文末海报中[二维码]或者点击这里[填写报名表]。
微信搜索ID[Hello_Slushers]添加Slush小助手微信，审核后会邀请您加入对应路演微信群，您可以在群内获得更多活动信息并与其他参会者进行高度互动。
Pitching Startups
Tailai Bioscience is a biotechnology company founded by medical experts and seasoned scientists, providing disruptive biopsy products and services based on proprietary multi-omics technology. We believe in Prevention Rather Than Cure.
TaiLai Biosciences team has been cooperating with world-renowned hospitals and thought-leaders for advanced cancer screening technology with multi-omics and machine learning based on a great number of clinical data. Our products and services make it possible to locate, identify, and intervene in the patients’ disease early enough, which could significantly increase the recovery rate.
泰莱生物由资深的医疗产业团队以及多位领域内顶级专家教授、博士、科学家组成的前沿科学团队联合创立，是一家提供基于专有的生物多组学技术的新一代活检产品和服务的生物科技公司。
我们信奉“防大于治”， 深耕于生物多组学及液体活检技术的科研及转化，通过研发的一系列疾病精准筛查技术服务，帮助大众客户更早发现健康隐患，实现有效防范；或让医生的诊疗在早期即可介入，大幅降低救治难度，提高生存率。
泰莱生物期待让更多前沿科技落地成现实，为人类提供更多疾病的精准诊疗方案。
Hopstem BioengineeringLtd. Co was established in Hangzhou, 2017, by neuroscience and stem cell scientists from Johns Hopkins University. Hopstem has established a world-leading platform of differentiating human embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC) into high-quality neural progenitor cells and functional subtypes of neural cells.
Hopstem devoted to developing cell replacement therapies with GMP-grade neural cells for those who suffer from neurological disorders, including stroke, traumatic brain injury, AD, PD and ALS, etc. On the other hand, Hopstem also provides physiological relevant human neural cells, brain organoids and services to promote in vitro disease modeling for drug discovery, high throughput drug screening, and toxicology studies for CNS disorders. With developed patents in iPSC reprogramming, neural differentiation, and 3D brain organoids technology innovation, Hopstem was voted among “Top 50 Most Innovative Chinese Biomedical Companies in 2019”.
浙江霍德生物工程有限公司是由美国约翰霍普金斯大学的神经及干细胞科学家于2017年在杭州创立的创新型生物医药及技术公司。公司自主研发了iPSC重编程方法，第二代的人神经分化技术，临床级神经前体细胞的制备体系，以及均一的3D类脑器官制备等技术。
团队所研发的人源细胞或类器官组织和技术可被广泛应用于脑卒中，自闭症，老年痴呆，ALS，脊髓损伤，帕金森症，癫痫，精神分裂症神经疾病的机理研究，药物筛选、药理毒理评估及临床治疗产品的研发等。霍德生物的目标是研发和转化最前沿的干细胞技术从而推进神经系统疾病的治疗。霍德生物凭借在iPSC重编程，神经分化和3D脑类器官技术创新方面的已开发专利，被评选为“ 2019年中国生物医学创新公司50强”。
Quantilogic Healthcare is a high-tech company specializing in medical imaging and medical data analysis. Our company is committed to the clinical translational research and applications of quantitative image analysis, radionics, and machine-learning technologies, developing software platforms for evaluation of treatment response in oncology and clinical trials. Our company's long-term goal is to establish an integrated medical data analysis platform for early cancer screening, computer-aided diagnosis, evaluation and prediction of treatment response.
浙江昆捷医疗科技有限公司是一家深根于医学影像和医疗数据分析的高科技公司。我们公司主要致力于影像量化分析、影像组学、机器学习等技术在临床转化方面的研究和应用，并开发相关的软件平台用于支撑肿瘤疗效评估和临床试验。我们公司长期目标在于建立综合医疗数据处理平台，用于早期肿瘤筛查、计算机辅助诊断、疗效评估及预测等。
D&P Bioinnovations, LLC, D&P is a regenerative medicine company focused on repairing damaged organs with engineered biomaterials and stem cells. The company has developed a platform absorbable immunomodulatory medical device implant to regenerate damaged organs: gastro-intestine, blood vessels, nerves, tendons/ligaments, and muscle. This platform technology can address the global regenerative medicine market that is expected to accrue over $110 billion by the mid-2020s. D&P’s first therapeutic indication is developing an implantable, bioresorbable medical device to regenerate a damaged esophagus (organ providing food to the stomach).
D＆P Bioinnovations，LLC 是一家再生医学公司，致力于利用工程生物材料和干细胞修复受损器官。该公司开发了一种可吸收平台的免疫调节医疗器械植入物，用于再生受损的器官：肠胃，血管，神经，腱/韧带和肌肉。该平台技术可以满足全球再生医学市场的需求，到2020年代中期，这一市场预计将超过1100亿美元。D＆P产品的第一个治疗适应症是开发一种可植入的，可生物吸收的医疗设备，以再生受损的食道。
xixilab HK LLC provides a tooth straightening service using invisible braces without the need for monthly office visits. No longer is it necessary to wait in line at a hospital to see a doctor - technology is transforming how healthcare is delivered and lowering the cost. By leveraging technology to monitor treatments, customers can achieve more successful treatments while saving time and money - xixilab is one-third of the market price. A beautiful smile is becoming a status symbol in China like it is abroad. As a result, oral health is one of the fastest-growing segments of beauty in China. xixilab uses advanced imported materials and an international dental team to create a truly personalized invisible braces experience.
xixilab香港有限责任公司通过隐形牙套，为用户提供不用每月频繁复诊的牙齿矫正服务。在医院排队等候看医生将不再成为必要——因为科技在降低成本的同时，也改变了医疗服务的交付方式。xixilab隐形牙齿矫正是市场价格的三分之一，通过利用技术监控治疗过程，用户可以在节省时间和金钱的同时获得更成功的治疗！在中国，美丽的微笑正像在国外一样成为一种身份象征。因此，口腔健康是中国发展最快的美容领域之一。xixilab采用先进的进口材料和国际口腔医生团队服务，为客户打造真正个性化的隐形牙齿矫正体验。
XFOLD is a nano surface that can be added to glass or plastic slides or sensors used for example in microscopy will 100 folds biomedical imaging without requirements to upgrade or modernize existing fleet of equipment nor change working processes. We are looking for 1M€ to transfer IP from University to be established company. Aside from IP, most of the investment requirements go to sales and marketing activities, running and expanding pilot customers, building mass production capabilities and expanding high volume application areas.
XFOLD的产品是一种纳米表面材料，可以添加到玻璃或塑料载玻片或传感器中，例如用于显微镜，可进行100倍的生物医学成像，而无需升级或现代化现有设备，也无需更改工作流程。我们正在寻找100万欧元从将技术从大学转移至公司。除此之外，我们也在寻求资金用于销售和营销活动，运行和扩展试点客户，建立批量生产能力以及扩展大批量应用的领域。
Jury&Panel Speaker
GaoPeng Chen
Zhenfund
Vice President
Gaopeng Chen is a Vice President at ZhenFund and focuses on early-stage healthcare opportunities.
Prior to joining ZhenFund, Gaopeng was an investment professional at Langsheng Investment. Gaopeng began his career at Eli Lilly China, where he participated in the development of multiple drugs.
Gaopeng received a B.S. from Sichuan University and obtained a Ph.D. from LKS Faculty of Medicine, the University of Hong Kong. He also conducted research at the Icahn School of Medicine at Mount Sinai.
陈高鹏是真格基金投资副总裁，聚焦生物医药领域投资。
加入真格基金之前，陈高鹏就职于朗盛投资。此前，他曾服务于礼来制药，从事药物临床研发，并参与多个药物注册上市。
陈高鹏取得了四川大学学士学位和香港大学李嘉诚医学院心肌再生博士，并曾在美国西奈山伊坎医学院从事科学研究。
Dr. Lv Wener
Microport
Director
Dr. Lv is the Business Development Director of MicroPort. Dr. Lv's primary responsibilities focus on the area of biomedical technology innovations, including the global investment and cooperation, incubation program for start-ups, and the leading of a Ph.D. team specializing in AI+ medical technologies.
Prior to his current position, Wener has served in a few biomedical start-ups and venture capital firms in the US. Dr. Lv was awarded a Ph.D.. from MIT and received his BSc and MSc from Tsinghua.
吕文尔博士是微创医疗商业发展部高级总监，主要聚焦在微创生物医学技术领域的创新，包括全球战略投资与合作，奇迹点孵化器，并担任AI医疗技术创新小组负责人。
吕文尔博士曾在美国数家生物医学创业公司及风险投资公司任职。吕文尔博士拥有麻省理工学院博士学位和清华大学学士硕士学位。
战略投资及合作案例：Robocath、NDR Medical、Rapid Medical等。
Juha
Health Capital Helsinki
Director
Juha leads Health Capital Helsinki (HCH), a health tech & life science ecosystem developing program, supported and funded by the largest cities, leading universities, and the main hospital in Finland.
Before joining HCH a year ago, Juha did a 30-year career in the pharmaceutical and biotech industry. Most recently he has been country manager for Sandoz (a Novartis company) and before that a Business Unit Director at GSK.
Health Capital Helsinki is building the greatest health capital in Helsinki. Due to the leading position in Finland and the best Nordic position towards Asia, HCH is helping you get connected with ecosystems & startups in Finland and in Nordic countries.
Juha担任赫尔辛基医疗资本投资总监，负责领导赫尔辛基健康资本和赫尔辛基生态系统开发计划，该计划由芬兰最大的城市，顶尖大学和主要医院提供支持和资助。
在加入HCH之前，Juha已在制药和生物技术行业工作了30年。他曾担任Sandoz（诺华公司）的国家经理，在此之前，他还是GSK的业务部门总监。
Inka Mero
Voima Ventures
Founder & Managing Partner
Inka Mero is the founder and managing partner of Voima Ventures, the first true deep tech VC fund in the Nordics. Voima Ventures invests in science-based startups and has a mission to solve global problems by combining science, entrepreneurship, and growth capital.
Inka has close to 25 years of global growth business, entrepreneurship, CEO, and VC investor experience from various technology-related businesses, including mobile software, gaming, e-commerce, big data & analytics, and deep tech. She is an investor in 50+ companies and serves on the board of several public companies.
Inka Mero是Voima Ventures的创始人和管理合伙人。Voima Ventures是北欧的深科技风险投资基金，投资于以科技为基础的初创公司，其使命是通过结合科学，企业家精神和资本来解决全球性问题。
Inka拥有近25年的全球业务增长，企业家精神实践，首席执行官和VC投资经验，涉及各种与技术相关的业务，包括移动软件，游戏，电子商务，大数据和分析以及深科技。她是50多家公司的投资者，并在多家上市公司董事会任职。
Chandler Chen
AstraZeneca
I·Campus Director
Chandler Chen is the I·Campus Director of AstraZeneca China. He is responsible for the overall development of the I·Campus, bringing in global innovative life-science companies into China market and provide value-add solutions from incubation, acceleration to commercialization. He will support the enhancement of AstraZeneca holistic solutions and platform strategy, by developing I·Campus towards an open innovation platform to global life science companies and AstraZeneca partners.
Chandler used to be the partner of first chain ambulatory surgery centers in China. Prior to that, Chandler was the investment director at Puhua Capital, investing in and managing 10 more life-science portfolio companies across the device, digital, distribution, insurance, and service sectors. Chandler received his MBA degree from CEIBS and Bachelor's degree in International Economics&Trade from China Foreign Affairs University.
陈锴是阿斯利康的国际生命科学创新园总监，负责国际生命科学创新园的打造，引入国内外创新的生命科学项目、提供从落地孵化到商业化加速的赋能，丰富阿斯利康的诊疗一体化创新方案并支持业务平台化战略，为国内外的生命科学企业及AZ合作伙伴提供开放创新的平台。
陈先生曾在国内第一家连锁手术中心担任合伙人兼战略发展总监，在此之前他曾在普华医疗基金担任投资总监，主导完成了10多家企业的股权投资并负责投后管理，涉及医疗器械、大数据、健康险、流通、服务等细分领域。陈先生是中欧国际工商学院的MBA，从外交学院获得国际经济与贸易的学士学位。
1:51:02 Highlights:Slush China 2020 'Reboot the Future' online pitching - AI+FinTech
About Slush “Reboot the Future“
Online Pitch Series
These series are meant to provide value for entrepreneurs during the difficult times of Covid-19 and encourage entrepreneurs to be radically innovative to create a new future.
During the past 3 months, we have organized three online pitches including on AI, IoT, and Fintech, which were well received in the startup ecosystem.
关于Slush“重启未来”线上路演
“重启未来”线上路演意在在疫情期间为创业者提供新的选择，鼓励创业者怀揣勇敢无畏的精神去开拓新秩序，创造未来。在过去3个月里，我们已经组织了人工智能、IoT、金融科技领域三场线上路演大赛，获得了创业圈的一致好评。
ABOUT SLUSH CHINA
Slush entered China in 2015 with its debut event in Beijing. Since 2016, Slush China brought this world-class tech event to Shanghai, Nanjing, Shenzhen, and welcomed more than 35,000 tech-heads, 3,000 volunteers, 4,000 startups, 500 speakers from all across the world. As one of Slush's global tech events, Slush China serves as a platform for global startups to meet top investors, corporate, and media. Forbes magazine listed Slush as a top international startup & technology event in China.
联系客服
